Stewart Deirdre, Desai Rooma, Cheng Qi, Liu Aiping, Forman Stuart A
Beecher/Mallincrodt Labs, Department of Anesthesia & Critical Care, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
Mol Pharmacol. 2008 Dec;74(6):1687-95. doi: 10.1124/mol.108.050500. Epub 2008 Sep 19.
The potent general anesthetic etomidate produces its effects by enhancing GABA(A) receptor activation. Its photolabel analog [(3)H]azi-etomidate labels residues within transmembrane domains on alpha and beta subunits: alphaMet236 and betaMet286. We hypothesized that these methionines contribute to etomidate sites formed at alpha-beta subunit interfaces and that increasing side-chain bulk and hydrophobicity at either locus would mimic etomidate binding and block etomidate effects. Channel activity was electrophysiologically quantified in alpha(1)beta(2)gamma(2L) receptors with alpha(1)M236W or beta(2)M286W mutations, in both the absence and the presence of etomidate. Measurements included spontaneous activation, GABA EC(50), etomidate agonist potentiation, etomidate direct activation, and rapid macrocurrent kinetics. Both alpha(1)M236W and beta(2)M286W mutations induced spontaneous channel opening, lowered GABA EC(50), increased maximal GABA efficacy, and slowed current deactivation, mimicking effects of etomidate on alpha(1)beta(2)gamma(2L) channels. These changes were larger with alpha(1)M236W than with beta(2)M286W. Etomidate (3.2 muM) reduced GABA EC(50) much less in alpha(1)M236Wbeta(2)gamma(2L) receptors (2-fold) than in wild type (23-fold). However, etomidate was more potent and efficacious in directly activating alpha(1)M236Wbeta(2)gamma(2L) compared with wild type. In alpha(1)beta(2)M286Wgamma(2L) receptors, etomidate induced neither agonist-potentiation nor direct channel activation. These results support the hypothesis that alpha(1)Met236 and beta(2)Met286 are within etomidate sites that allosterically link to channel gating. Although alpha(1)M236W produced the larger impact on channel gating, beta(2)M286W produced more profound changes in etomidate sensitivity, suggesting a dominant role in drug binding. Furthermore, quantitative mechanistic analysis demonstrated that wild-type and mutant results are consistent with the presence of only one class of etomidate sites mediating both agonist potentiation and direct activation.
强效全身麻醉药依托咪酯通过增强GABA(A)受体激活来发挥作用。其光标记类似物[(3)H]叠氮依托咪酯标记α和β亚基跨膜结构域内的残基:α亚基的Met236和β亚基的Met286。我们推测这些甲硫氨酸有助于在α-β亚基界面形成依托咪酯结合位点,并且在这两个位点增加侧链体积和疏水性将模拟依托咪酯结合并阻断依托咪酯的作用。在不存在和存在依托咪酯的情况下,对具有α(1)M236W或β(2)M286W突变的α(1)β(2)γ(2L)受体的通道活性进行电生理定量。测量包括自发激活、GABA的半数有效浓度(EC(50))、依托咪酯激动剂增强作用、依托咪酯直接激活作用以及快速宏观电流动力学。α(1)M236W和β(2)M286W突变均诱导通道自发开放,降低GABA的EC(50),增加GABA的最大效能,并减慢电流失活,模拟了依托咪酯对α(1)β(2)γ(2L)通道的作用。α(1)M236W引起的这些变化比β(2)M286W引起的变化更大。在α(1)M236Wβ(2)γ(2L)受体中,3.2 μM的依托咪酯使GABA的EC(50)降低的幅度(2倍)远小于野生型(23倍)。然而,与野生型相比,依托咪酯在直接激活α(1)M236Wβ(2)γ(2L)方面更有效且效能更高。在α(1)β(2)M286Wγ(2L)受体中,依托咪酯既不诱导激动剂增强作用也不诱导直接通道激活。这些结果支持以下假设:α(1)的Met236和β(2)的Met286位于与通道门控变构连接的依托咪酯结合位点内。尽管α(1)M236W对通道门控的影响更大,但β(2)M286W对依托咪酯敏感性的改变更显著,表明其在药物结合中起主导作用。此外,定量机制分析表明,野生型和突变体的结果与仅存在一类介导激动剂增强作用和直接激活作用的依托咪酯结合位点一致。